Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Randomized, double-blind, placebo-controlled trial of probiotics combination Clinical research on treatment of colorectal cancer

ABSTRACT: Interventions: Colorectal cancer control group:no;Colorectal cancer probiotics group:No Primary outcome(s): Intestinal flora metabolomics;Intestinal mucosal barrier;Inflammatory factors;Observation of clinical efficacy indicators;Intestinal flora Study Design: Parallel

DISEASE(S): Colorectal Cancer

PROVIDER: 2759602 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Intestinal microecological changes and its mechanism in patients with thyroid tumor

Project description:Interventions: Experimental group:Giving probiotics;Control group:No probiotics Primary outcome(s): Copper, zinc, calcium, magnesium and iron;Inflammatory factors;Intestinal mucosal barrier;Intestinal flora Study Design: Parallel

| 35345 | ecrin-mdr-crc

Effectof postoperative Bifidobacterium lactis M8 on intestinal flora andimmune function in patients with colorectal cancer

Project description:Interventions: Probiotics Group:Bifidobacterium lactis M8;2:Intestinal antimicrobials Primary outcome(s): Intestinal flora;Intestinal barrier function;Humoral immune function;cellular immune function Study Design: Randomized parallel controlled trial

| 2678440 | ecrin-mdr-crc

The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription; a randomized double-blind placebo controlled trial

Project description:The aim of this study was to investigate the effects of three Lactobacillus plantarum strains on in-vivo small intestinal barrier function and gene transcription in human subjects. The strains were selected for their differential effects on TLR signalling and tight junction protein rearrangement, which may lead to beneficial effects in a stressed human gut mucosa. Ten healthy volunteers participated in four different intervention periods: 7-day oral intake of either L. plantarum WCFS1, CIP48 (CIP104448), TIFN101 (CIP104450) or placebo, proceeded by a 4 weeks wash-out period. Lactulose-rhamnose ratio (an indicator of small intestinal permeability) increased after intake of indomethacin, which was given as an artificial stressor of the gut mucosal barrier (mean ratio 0.06±0.04 to 0.10±0.06, p=0.001), but was not significantly affected by the bacterial interventions. However, gene transcription pathway analysis in small intestinal biopsies, obtained by gastroduodenoscopy, demonstrated that particularly L. plantarum TIFN101 modulated cell-cell adhesion with high turnover of genes involved in tight- and adhesion junction protein synthesis and degradation (e.g. actinin alpha-4, metalloproteinase-2). These effects were less pronounced for L. plantarum WCFS1 and CIP104448. In conclusion, L. plantarum TIFN101 induced the most pronounced probiotic properties with specific effects on repair processes in the compromised intestine of healthy subjects.

2017-02-09 | GSE74988 | GEO

Effect of probiotics on intestinal barrier function and enterotoxicity in patients with colorectal cancer undergoing chemotherapy

Project description:Interventions: experimental group:Probiotics;control group:placebo Primary outcome(s): Intestinal flora;IL-6;Plasma D-lactate Study Design: Parallel

| 2691887 | ecrin-mdr-crc

A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer.

Project description: Not available

| S-EPMC6657028 | biostudies-literature

Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.

Project description: Not available

| S-EPMC4603068 | biostudies-literature

Prevention of radiotherapy induced enteropathy by probiotics (PREP): protocol for a double-blind randomized placebo-controlled trial.

Project description: Not available

| S-EPMC8444386 | biostudies-literature

Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial.

Project description: Not available

| S-EPMC7014653 | biostudies-literature

Alterations in the gut microbiota and metabolic profiles coincide with intestinal damage in mice with a bloodborne Candida albicans infection

Project description:Candida albicans is an opportunistic fungus that can threaten life especially in patients with candidemia. The morbidity and mortality of candidemia originating from a central venous catheter (CVC) and illicit intravenous drug use (IVDU) are increasing. However, the mechanism underlying the bloodborne C. albicans infection remains unclear. Herein, we evaluated the gut microbiome, metabolites and intestinal mucosa by constructing the mouse models with candidemia. Model mice were injected with C. albicans via tail vein. Control mice underwent sham procedures. We observed basic life characteristics, intestinal damage-related alterations using hematoxylin and eosin (H&E) staining, intestinal tight junction protein levels, and intestinal permeability in these mice. Fecal samples were analyzed by performing 16S rRNA gene sequencing of the microbiota and LC-MS metabolomics to reveal the perturbations in intestinal flora and metabolism exacerbating intestinal damage. Weight loss, a decreased survival rate, C. albicans infection spread, and colonic epithelial damage occurred in the model group. Furthermore, the intestinal flora abundance was reduced. Several probiotics, such as Lactobacillus, and butyrate-producing bacteria, including Roseburia, Lachnospiraceae, and Clostridia, were depleted, and some pathogenic bacteria, such as Escherichia-Shigella and Proteus, belonging to the Proteobacteria phylum, and the inflammation mediators Ruminococcus and Parabacteroides were enriched in model mice. Multiple differentially altered metabolic pathways were observed and mainly related to bile acid, arachidonic acid, bile secretion, and arachidonic acid metabolism. This study illustrated the effects of a bloodborne C. albicans on the intestinal microbiota, metabolites, and intestinal barrier, which may provide new insights into tests or treatments for candidemia originating from CVC or IVDU.

2021-04-13 | MTBLS1918 | MetaboLights

Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

Project description: Not available

| S-EPMC6950464 | biostudies-literature